ArriVent BioPharma, Inc. (AVBP) · Oct 6, 2026 · Other events

ArriVent clinical trial misses Phase 3 endpoint; drug in doubt

Below the bar — Primary PFS endpoint not met by blinded independent review

ArriVent’s FURVENT clinical trial missed its primary PFS endpoint, putting its lead lung-cancer drug’s development path under review.

ArriVent is a clinical-stage oncology biotech built around firmonertinib, with the company trying to establish the drug in first-line lung cancer while expanding into antibody-drug conjugates. Before this filing, FURVENT was the key near-term value inflection: topline data were expected in the second half of 2026, and the company’s broader plan still depended heavily on firmonertinib’s two global Phase 3 programs.

The pivotal trial failed its core test. FURVENT did not meet its primary endpoint of progression-free survival by blinded independent central review, the prespecified standard intended to determine whether firmonertinib beat platinum-based chemotherapy. 〔0〕 That places the result below the trial’s success bar, regardless of favorable signals in investigator-assessed PFS, response rate, or an immature overall-survival trend.

The filing’s positive secondary signals do not repair the main miss. Management explicitly says the study did not show a meaningful PFS improvement over chemotherapy by BICR, which is the cleanest read on the result. 〔1〕 The secondary-endpoint benefits may preserve questions around subgroups or later analyses, but they do not establish the first-line efficacy claim the Phase 3 trial was designed to prove.

Safety was acceptable, but not enough to offset the efficacy failure. Severe treatment-emergent adverse events were broadly similar across the arms, while severe treatment-related events were numerically lower with firmonertinib than chemotherapy. The filing reports no new safety signal, but a tolerable profile cannot by itself support approval when the primary efficacy endpoint failed. 〔2〕

Filing metricFirmonertinib 240 mgFirmonertinib 160 mgControl arm
Grade ≥3 treatment-emergent adverse events (Safety data)52%53%55%
Grade ≥3 treatment-related adverse events (Safety data)26%22%40%

The company now has to reassess its lead-program strategy. ArriVent says it is reviewing the full FURVENT dataset and deciding the most appropriate development path for firmonertinib. The drug’s other major clinical opportunity, the ALPACCA Phase 3 study in first-line PACC-mutant NSCLC, remains active, but this failure weakens the broader thesis that firmonertinib can become a differentiated first-line treatment across uncommon EGFR mutations. The company had reported $373.1 million of cash and investments as of June 30, 2026, expected to fund operations into 2028, so the immediate issue is program credibility and development scope rather than an obvious near-term financing need.

Bottom line: This is a material setback to ArriVent’s central drug thesis, not a routine data update. Secondary signals and clean safety may justify further analysis, but the failed independent-review PFS endpoint leaves firmonertinib’s first-line FURVENT path substantially impaired.

What to watch next

Full FURVENT dataset review and development-path decision

Original filing on SEC EDGAR

More ArriVent BioPharma, Inc. news

ArriVent clinical trial misses Phase 3 endpoint; drug in doubt | AVBP Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.